Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $5.9 million.

  • Fulcrum Therapeutics' Non-cash Items rose 35594.32% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 35594.32%. This contributed to the annual value of $5.4 million for FY2024, which is 6457.96% down from last year.
  • Fulcrum Therapeutics' Non-cash Items amounted to $5.9 million in Q3 2025, which was up 35594.32% from $22.2 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Non-cash Items ranged from a high of $35.1 million in Q1 2024 and a low of $3971.0 during Q2 2022
  • Its 5-year average for Non-cash Items is $8.0 million, with a median of $3.4 million in 2021.
  • In the last 5 years, Fulcrum Therapeutics' Non-cash Items plummeted by 9989.96% in 2022 and then soared by 7013034.5% in 2023.
  • Over the past 5 years, Fulcrum Therapeutics' Non-cash Items (Quarter) stood at $27.1 million in 2021, then tumbled by 93.04% to $1.9 million in 2022, then soared by 701.74% to $15.1 million in 2023, then crashed by 64.58% to $5.4 million in 2024, then grew by 10.41% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $22.2 million for Q2 2025, and $150489.0 during Q1 2025.